Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Bristol-Myers Squibb’s Opdivo Immunotherapy Receives FDA Approval for Bladder Cancer

XTALKS VITALS NEWS

Immuno-Oncology

The immunotherapy is approved for a number of other indications, including the treatment of metastatic melanoma, non-small cell lung cancer, and advanced renal cell carcinoma.

Share this!

February 7, 2017 | by Sarah Hand, M.Sc.

Bristol-Myers Squibb’s immuno-oncology drug, Opdivo, has received US Food and Drug Administration (FDA) approval to treat patients with a common form of bladder cancer, known as urothelial carcinoma. The immunotherapy is approved for a number of other indications, including the treatment of metastatic melanoma, non-small cell lung cancer, and advanced renal cell carcinoma.

The expanded indication will specifically affect cancer patients with locally advanced or metastatic urothelial carcinoma who show disease progression despite treatment with platinum-containing chemotherapy. Patients with disease progression within one year of receiving neoadjuvant or adjuvant chemotherapy, will also be eligible to be treated using the injectable.

“Our goal to help more patients is further realized in today’s approval for Opdivo in this population and we are excited that our immuno-oncology therapy is now an option and potential hope for these patients,” said Chris Boerner, president of U.S. Commercial, Bristol-Myers Squibb. “This is evidence of our commitment to immuno-oncology and to bringing therapies, like Opdivo, to more and more patients in need of additional choices.”



The FDA’s decision was made based on the results of a Phase II open-label clinical trial which involved 270 patients with urothelial carcinoma. The safety and efficacy study found that nearly 20 percent of patients responded to treatment with Opdivo.

While only 2.6 percent of patients experienced a complete response, the remaining 17 percent showed at least a partial response. Bristol-Myers Squibb reported that the median duration of response among responders was 10.3 months, with the median time to response coming in at 1.9 months.

“Most people don’t know how common bladder cancer is and that it is the fifth most diagnosed cancer. That’s why we are dedicated to raising awareness and supporting research efforts that may offer more treatment options to patients who need them,” said Stephanie Chisolm, director of Education and Research at Bladder Cancer Advocacy Network. “This approval is another exciting step forward for the bladder cancer community and provides needed hope to patients and their families.”

Bristol-Myer’s Squibb’s application for Opdivo in bladder cancer was granted priority review by the FDA. The approval is based upon both tumor response rate and duration of response, however it may be contingent upon confirmation of results in future clinical trials.


Keywords: Immuno-Oncology, FDA, Bladder Cancer


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Canadian Regulator Recalls Pie Shells Over E. Coli Contaminated Flour

April 28, 2017 - Multiple brands of pie and tart shells are being recalled in Canada after the flour used to manufacture them was linked to 28 cases of illness due to infection with E. coli O121.

Featured In: Food News


FDA Sends Warning Letters to Manufacturers of Fake Cancer Drugs

April 27, 2017 - The FDA is cracking down on the sale of illegal cancer drugs by sending warning letters to 14 US companies selling the unapproved products.

Featured In: Life Science News, Drug Safety News


Womb-Like Device Could Increase Survival of Premature Babies

April 27, 2017 - Researchers at the Children's Hospital of Philadelphia (CHOP) have developed a womb-like device which mimics the environmental conditions found inside the uterus.

Featured In: Life Science News, Medical Device News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

What Medical Device Manufacturers Need to Know Before Developing a Biological Safety Evaluation

REGISTER FOR THESE WEBINARS

Technology Solutions for Late Phase Research: Optimising Real World Data Assets


Serialization for Late Starters – With Live Industry Research Results


Clinical Not All Antioxidants Are Created Equal: Astaxanthin, The Antioxidant Powerhouse


The New Gold Standards of IRT Delivery for Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.